Home » Bruker Licenses IP from Erasmus Medical Center

Bruker Licenses IP from Erasmus Medical Center

Jan 03, 2013
|
staff reporter

NEW YORK (GenomeWeb News) – Bruker today announced it has licensed intellectual property from the Erasmus Medical Center for the rapid testing of beta-lactamase activity using MALDI-TOF technology.

The method being licensed is compatible with the Bruker MALDI Biotyper system, which uses MALDI-TOF mass spectrometry for identifying microorganisms, the company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Scan

An RNAi Approval

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Keep It Going

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Stop It There

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

This Week in PLOS

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.

Aug
23
Featured Webinar

Automated High-Throughput Protein Production of Human Proteins and Antibodies

Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.

What's Popular?

In Proteomics & Protein Research

  1. BD Expands Rhapsody System to Include Single-Cell Protein Analysis

    Premium

  2. Newomics Closes $3.9M Series A Round

  3. Expedeon Posts 106 Percent Jump in Q2 Revenues

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.